Gara Jalqabaatti › Non-Hodgkin Lymphoma › Massachusetts
Qorannoo klinikaalii Non-Hodgkin Lymphoma Massachusetts keessatti
Qorannoo 28 Non-Hodgkin Lymphoma f Massachusetts keessatti hirmaatuu jiru.
Magaalota Massachusetts keessatti
Takkalaa qorannoo (Ingiliffa)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT05006716Epco, Zanu, Ritux for R/R FL or MZL
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06563596A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07101328AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Research Site, Boston
- Research Site, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT06137144A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT06090539Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Boston Medical Center, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT06806033A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Ful-2026 · NCT06854653Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Tufts Medical Center, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 08-Ful-2026 · NCT03666000Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
12 Months – 30 Years · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT04851119A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Massachusetts General Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 19-Hag-2026 · NCT04104776Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Hag-2026 · NCT06116110A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Brigham and Women's Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1Hojjettoota fayyaa simatamoo
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 28-Ado-2026 · NCT07020533DALY II USA/ MB-CART2019.1 for DLBCL
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Ado-2026 · NCT04792489A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 06-Ado-2026 · NCT01351545Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 13 fi ol · Saalaa hunda · Haaromfame 05-Cam-2026 · NCT04771572Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Elb-2026 · NCT00131014CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Elb-2026 · NCT03328078Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
- Dana Farber Cancer Institute, Boston
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Elb-2026 · NCT06923397CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
- Massachusetts General Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Bit-2026 · NCT06026319Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
- Beth Israel Deaconess Medical Center, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Bit-2026 · NCT06510361CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- DFCI/BWH Brigham and Women's Hospital, Boston
Namoota walitti qabaa jiraSadarkaa 2Hojjettoota fayyaa simatamoo
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 10-Bit-2026 · NCT06059391A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 4
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Bit-2026 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 4
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Bit-2026 · NCT06876649Study of SGR-1505 in Mature B-Cell Neoplasms
- Beth Israel Deaconess Medical Center, Boston
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Gur-2026 · NCT05544019AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- University of Massachusetts Memorial Medical Center, Worcester
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Mud-2025 · NCT05602363Emapalumab Prevention of CAR-T Cell Associated Toxicities
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Sad-2025 · NCT06550141SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 28-Onk-2025 · NCT03452774Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.